These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15929802)

  • 21. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG
    Crit Rev Oncol Hematol; 2001 Apr; 38(1):17-23. PubMed ID: 11255078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Panitumumab: a summary of clinical development in colorectal cancer and future directions.
    Argiles G; Dienstmann R; Elez E; Tabernero J
    Future Oncol; 2012 Apr; 8(4):373-89. PubMed ID: 22515440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cetuximab in the treatment of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Expert Opin Biol Ther; 2007 Feb; 7(2):243-56. PubMed ID: 17250462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
    Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
    J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacological and clinical profiles of panitumumab injection (Vectibix®)].
    Matsudaira T; Asahi D; Yana I; Aboshi M
    Nihon Yakurigaku Zasshi; 2011 Jan; 137(1):31-41. PubMed ID: 21233587
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih M
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
    Giusti RM; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
    Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
    Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Panitumumab.
    Chua YJ; Cunningham D
    Drugs Today (Barc); 2006 Nov; 42(11):711-9. PubMed ID: 17171190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
    Weber J; McCormack PL
    BioDrugs; 2008; 22(6):403-11. PubMed ID: 18998757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?
    Peeters M; Price T; Van Laethem JL
    Oncologist; 2009 Jan; 14(1):29-39. PubMed ID: 19144681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
    Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
    Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer.
    Peeters M; Balfour J; Arnold D
    Aliment Pharmacol Ther; 2008 Aug; 28(3):269-81. PubMed ID: 19086328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer.
    Bekaii-Saab T
    Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):5-13. PubMed ID: 31730590
    [No Abstract]   [Full Text] [Related]  

  • 40. Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials.
    Koukakis R; Gatta F; Hechmati G; Siena S
    Qual Life Res; 2016 Oct; 25(10):2645-2656. PubMed ID: 27083443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.